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Objectives: It has been observed that restrictive pulmonary function is associated with obesity
and C-reactive protein (CRP), an indicator for systemic inflammation. However, the
interrelationship among body composition, CRP, and restrictive pulmonary function has been
poorly understood. This study focused on the combined effects of body composition and
CRP on restrictive pulmonary function.
Methods: We performed a cross-sectional study to examine the association of body
composition and CRP with restrictive pulmonary function in 12,787 subjects (7083 men, 5704
women; ages 20e75 yr). We evaluated body composition and CRP as a categorical variable
(non-obesity, percentage body fat 75 percentile; obesity, percentage body fat >75
percentile; low-inflammation, CRP 75 percentile; high-inflammation, CRP >75 percentile)
and constructed 4 groups, which were non-overlapping (reference, inflammatory, obese, obese
and inflammatory). The odds ratios (ORs) and 95% confidence intervals (CIs) for restrictive
pulmonary function were calculated across all 4 groups.
Results: The adjusted ORs (95% CIs) for restrictive pulmonary function according to the 4
groups were 1.00(reference), 1.19(0.93e1.52), 2.01(1.53e2.64) and 3.51(2.60e4.74) in men
and 1.00 (reference), 1.26 (0.96e1.69), 1.02 (0.58e1.81), and 3.32 (2.09e5.27) in women after
adjusting for confounding variables. Interaction was found between the body fat percentage
and CRP in women only (P < 0.05).
Conclusions: In summary, the coexistence of high fat accumulation and systemic subclinical
inflammation is associated with restrictive pulmonary function.
ª 2010 Elsevier Ltd. All rights reserved.nt of Family Medicine, Yonsei University College of Medicine, 23 Yongmun-ro, Yongin-city, Gyeonggi-
: þ82 31 331 5551.
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1198 D.-H. Jung et al.Introduction The study was approved by the Institutional Review Board atImpaired lung function has attracted growing interest as
a potentially novel risk factor for insulin resistance,1,2 type
2 diabetes,3 and coronary heart disease.4 Several epide-
miologic studies have also shown that impaired pulmonary
function, particularly the restrictive type, is associated
with obesity.5,6
Sincebodymass index (BMI) is known tobeassociatedwith
both fat mass and fat free mass, conflicting results of the
association between BMI and pulmonary function tests have
been reported.7,8 BMI is a major index in evaluating obesity,
but direct measurement of body fat composition and its
distributionmay bemore important in explaining the effects
of obesity on respiratory function.9e11 However, previous
studies about the association between adiposity and lung
function have generally used BMI as a marker of obesity.12 In
the present study, we sought to determine whether body fat
percentage instead of BMI, as a measurement of obesity, is
associated with pulmonary function.
Chronic low-grade inflammation may also exist in the
lung, independent of obesity.13e15 During the process of gas
exchange, the lung is exposed to various microorganisms
and a group of noxious gases. Thus, there are many
inflammatory cells involved in the protection of the
pulmonary tree against infectious agents, dusts, and
chemicals. In this regard, the lung is considered a source of
low-grade systemic inflammation.16 The cytokines gener-
ated by inflammatory cells enter the systemic circulation,
where they stimulate the liver to release C-reactive protein
(CRP).17,18 Inflammatory markers, such as CRP and IL-6,
have been associated with impaired pulmonary function
among subjects with metabolic syndrome and diabetes.19
Aronson et al. also showed this relationship in apparently
healthy subjects.16
However, little is known about the joint effect of CRP
and body fat composition on impaired lung function.
Therefore, we examined the relationship of body fat
composition as a marker of obesity and CRP with impaired
lung function in the Korean adults.Methods
Study population
The study was carried out in Gangnam Severance Hospital in
Korea between March 2006 and October 2008. A total of
13,555 healthy subjects (age range, 20e75 years) were
recruited from candidates who live in Seoul. They visited
a health promotion center to check risk factors for cardio-
vascular disease and cancer. Subjects completed a ques-
tionnaire that included items such as age, sex, smoking,
alcohol habits, exercise, and medical history. Subjects with
cardiovascular system disease, cancer, chronic bronchitis,
asthma, or structural deformities in their upper respiratory
tracts, or thosewhowere using drugs thatmay have affected
their pulmonary function test, were not included in the
study. Subjects with CRP levels of >10.0 mg/L were also
excluded from this study due to the possibility of infection.
The remaining 12,787 subjects were included in this study.Gangnam Severance Hospital, Yonsei University College of
Medicine, Seoul, Korea.
Anthropometric measurements
All subjects were required to fast for 10e12 h before the
measurement procedure. Height and weight were
measured using an automatic scale. BMI (kg/m2) was
calculated as weight (in kilograms) divided by square of the
height (in meters). Bioelectrical impedance analysis (BIA)
was used to assess body composition (X-scan PlusII, Jawon
Medical, Seoul, Korea), which was validated with regards to
reproducibility and accuracy for body composition.
Spirometry
Pulmonary function test assessment was performed using
a Model 1022 Spirometer (SensorMedics, USA). The same
technician performed all spirometric tests to reduce inter-
rater variability. Forced vital capacity (FVC) and forced
expiratory volume in 1 s (FEV1) from the best tests were
recorded, which was defined in accordance with American
Thoracic Society recommendations.20 Published prediction
equations were used to calculate predicted FEV1 and FVC
for each subject.21 Percentages of the predicted FVC (FVC
(%)) were calculated. A FEV1/FVC ratio of more than 0.7
and FVC (%) less than 0.8 were used to define impaired
restrictive pulmonary function.22
Laboratory measurements
Venous blood was collected from each subject after a 12-h
fast from an antecubital vein. High-sensitivity CRP was
measured using a latex-enhanced immunoturbidimetric
method with the lower limit of detection at 0.02 (mg/L)
(Roche Diagnostics, Indianapolis, IN, USA). Fasting plasma
glucose, total cholesterol, triglyceride, and high-density
lipoprotein (HDL) cholesterol levels were measured by
enzymatic methods using a Hitachi 7600-110 automated
chemistry analyzer (Hitachi, Tokyo, Japan). Diabetes was
defined as a self-reported history of the disorder or history
of taking anti-diabetic drugs or a fasting plasma glucose
level 126 mg/dL. Hypertension was defined as a self-
reported history of the disorder or history of taking anti-
diabetic drugs, systolic blood pressure 140 mmHg, or
diastolic blood pressure 90 mmHg. Regular exercise was
defined as more than 30 min of aerobic exercise at least
twice per week.
Statistical analysis
We defined the 75 percentile value as the cut-off point of
percent body fat and CRP. To assess the joint effects of
inflammation and body fat accumulation on restrictive
pulmonary function, we divided the 4 groups into subgroups
as follows: reference group (percentage body fat 75
percentile and, CRP 75 percentile); inflammatory group
(percentage body fat 75 percentile and, CRP >75
percentile); obese group (percentage body fat >75
percentile, CRP 75 percentile); and obese and
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CRP >75 percentile). We separated men and women in all
analyses because fat composition and CRP levels differ
significantly by sex. Demographic and biochemical charac-
teristics of the study population were summarized. All
continuous variables are presented as means (SD) or
medians (IQR), and the categorical variables are summa-
rized as percentages in each group. Due to skewness, CRP
was log transformed before statistical analyses. Pearson
correlation coefficients were determined for FVC (%) and
FEV1/FVC versus BMI, percentage body fat (%), and log CRP,
in men and women. The odds ratio for impaired lung
function was calculated using a multivariate logistic
regression analysis after adjusting for confounding vari-
ables across groups. The effect of the interaction between
CRP and body fat accumulation on the risk of impaired
pulmonary function was examined by multivariated logistic
regression. All analyses were conducted using SPSS statis-
tical software (version 15.0, Chicago, IL). All statistical
tests were 2-sided and statistical significance was deter-
mined at a p-value <0.05.
Results
The demographic and biochemical characteristics of the
study population according to body fat accumulation and
CRP are presented in Tables 1 and 2. The 75 percentile of
body fat percentage was 25.5% in men and 31.4% in women.
The 75 percentile of CRP was 1.4 mg/dL in men and 0.9 mg/





Age (yr) 45.1 (10.5) 46.5 (1
Body mass index (kg/m2) 23.3 (2.2) 23.8 (2
Body fat percentage (%) 20.4(3.8) 21.4 (3
Smoking status (%) Never 49.5 45.4
Current 31.2 38.2
Ex 19.4 16.4
Regular exercise (%) 47.7 54.1
Systolic blood pressure (mmHg) 124.7 (14.2) 126.4 (
Diastolic blood pressure (mmHg) 78.1 (9.2) 79.2 (9
Fasting plasma glucose (mmol/L) 5.24 (1.62) 5.41 (1
Non HDL-cholesterol (mmol/L)e 3.49 (0.84) 3.62 (0
Hypertension (%)f 21.5 25.0
Diabetes (%)g 5.7 8.4
FVC (%) 92.9 (10.0) 91.9 (1
FEV1/FVC 82.1 (6.7) 80.7 (7
Abbreviations: FVC, forced vital capacity; FEV, forced expiratory volu
a Data is expressed as the mean (SD) or percentage.
b P-value was calculated by comparing men and women using the 1
c Inflammatory group was defined as CRP 1.4 mg/L, which was the
d Obese group was defined as percentage body fat 25.5%, which wa
e Non HDL-cholesterol was defined as the total cholesterol - HDL-ch
f Hypertension was defined as an SBP 140 mmHg, DBP 90 mmHg
g Diabetes was defined as fasting plasma glucose level 126 mg/dLwas the highest in subjects with both obesity and high-
inflammation in men and women. The prevalence of
restrictive patterns of pulmonary function was 623 (8.8%) in
men and 536 (9.4%) in women. The results of the simple
linear model are presented in Table 3, showing a negative
association between log CRP and FVC, FEV1, and FEV1/FVC
in men. The association between body fat percentage and
FVC, FEV1, and FEV1/FVC was also significantly negative in
men, but this association is not the same in women. Only
FEV1/FVC is negatively related with log CRP and body fat
percentage in women.
Multivariate logistic regression models were used to
evaluate the joint effect of high fat accumulation and
chronic low-grade inflammation in the presence of impaired
pulmonary function. Compared to the reference group
having neither inflammation nor obesity, the odds ratios
(ORs) and 95% confidence intervals (CIs) of the high-
inflammatory group for restrictive pulmonary function
were 1.19 (0.93e1.52) in men and 1.26 (0.96e1.69) in
women, 2.01 (1.53e2.64) for the obese group in men and
1.02 (0.58e1.81) in women, and 3.51 (2.60e4.74) for both
with high-inflammatory and the obese group in men and
3.32 (2.09e5.27) in women after adjustment for all base-
line covariates. Table 4 indicates that subjects with both
inflammation and fat accumulation have an increased risk
of impaired pulmonary function, compared with not only
the reference group but subjects with only one component.
Before we divided all men and women into 4 groups, we
conducted a logistic regression analysis to confirm if there
is an interaction between CRP and body fat accumulationlation according to CRP and percentage body fat quartiles in




4.2) 47.1 (10.6) 46.0 (11.1) <0.001
.3) 26.9 (2.2) 27.6 (2.5) <0.001





14.7) 131.4 (14.5) 133.7 (14.7) <0.001
.5) 82.5 (9.3) 83.9 (9.5) <0.001
.04) 5.39 (0.92) 5.56 (0.85) <0.001
.88) 3.75 (0.8) 4.02 (0.88) <0.001
40.0 44.2 <0.001
5.7 7.2 <0.001
0.4) 91.8 (10.8) 88.8 (10.2) <0.001
.6) 81.7 (6.0) 81.7(7.5) <0.001
me.
-way ANOVA test or chi-square test.
cut-off value of the 75 percentile in the study population.
s the cut-off value of the 75 percentile in the study population.
olesterol.
, or history of the disorder.
or a history of the disorder.










n 3553 729 771 651 <0.001
Age (yr) 42.6 (13.6) 45.0 (10.5) 51.6 (10.6) 52.8 (11.1) <0.001
Body mass index (kg/m2) 21.0 (1.9) 21.8 (2.1) 25.7 (2.1) 26.6 (2.6) <0.001
Body fat percentage (%) 25.6 (3.6) 27.0 (3.4) 33.7 (2.1) 34.6 (2.5) <0.001
Smoking status (%) Never 90.9 90 95.3 94.8 <0.001
Current 6.2 7 3.8 3.8
Ex 2.9 3 0.9 1.4
Regular exercise (%) 58.6 59.9 58.6 58.9 0.517
Systolic blood pressure (mmHg) 113.7 (14.3) 116.4 (16.1) 124.9 (15.4) 130.1 (16.9) <0.001
Diastolic blood pressure (mmHg) 70.7 (9.2) 72.1 (9.9) 77.1 (9.1) 79.8 (9.9) <0.001
Fasting plasma glucose (mmol/L) 4.8 (0.66) 4.93 (0.77) 5.11 (0.71) 5.41 (1.13) <0.001
Non HDL-cholesterol (mmol/L)e 118.0 (29.8) 127.9 (36.1) 139.1 (32.6) 150.6 (35.3) <0.001
Hypertension (%)f 7.9 14.8 26.5 37.7 <0.001
Diabetes (%)g 1.4 3.3 3.4 7.2 <0.001
FVC (%) 92.8 (11.7) 92.4 (11.3) 98.3 (11.6) 95.4 (12.2) <0.001
FEV1/FVC 85.8 (6.5) 84.8 (7.3) 83.6 (5.3) 84.2 (27.6) <0.001
a Data is expressed as the mean (SD) or percentage.
b P-value was calculated by comparing men and women using the 1-way ANOVA test or chi-square test.
c Inflammatory group was defined as CRP 0.9 mg/L, which was the cut-off value of the 75 percentile in the study population.
d Obese group was defined as percentage body fat 31.1%, which was the cut-off value of the 75 percentile in the study population.
e Non HDL-cholesterol was defined as the total cholesterol - HDL-cholesterol.
f Hypertension was defined as an SBP 140 mmHg, DBP  90 mmHg, or a history of the disorder.
g Diabetes was defined as fasting plasma glucose level 126 mg/dL or a history of the disorder.
1200 D.-H. Jung et al.and the risk of restrictive pulmonary function. We found
that there was a significant interaction between CRP and
body fat accumulation in women (P Z 0.004) and not in
men (P Z 0.497).Discussion
In this study, we confirmed that obesity was associated with
deterioration in pulmonary function profiles. We also
showed that accumulation of body fat potentially contrib-
utes to the increased risk of a restrictive type of pulmonary
function, particularly when it was combined with elevated
CRP. These findings are in agreement with previous studies.
In 2744 elderly British men, Wannamethee et al. reported
that the percentage of body fat was negatively associated
with FEV1 and FVC.
23 Joshi et al. also showed this negative
association between body fat percentage and pulmonary
function in young individuals.24
Some studies have demonstrated that BMI, an indicator
of obesity, is associated with reduced lung function,
whereas others have shown inconsistent results. Lazarus
et al. suggested that BMI was not associated with FVC,8
but Steele et al. reported that BMI was associated with
lower FVC.7 Higher BMI represents not only fat mass, but
also fat free mass.23 Previous studies have shown that fat
free mass is positively associated with lung function.25,26
Thus, BMI itself provides insufficient information on body
fat distribution or body composition, which is an impor-
tant determinant of the effect of obesity on pulmonary
function.27 In the present study, BMI positively correlatedwith FVC (%) only in women, not significantly in men (data
not shown).
There are several potential mechanisms where excess
body fat might lead to reduced lung function. Increased
abdominal adiposity may impede the descent of the
diaphragm and increase thoracic pressure.5,28 Also, the
deposition of fat on the chest wall may impede excursion
and expansion of the rib cage through alteration in inter-
costal muscle function or by loading effect.29 Furthermore,
fat accumulation per se is closely associated with chronic
low-grade inflammation. Lee et al. reported that elevated
CRP was associated with reduced FVC among individuals
with metabolic syndrome.19
We separated groups both by fat accumulation and by
CRP because it is known that there are differences among
obesity populations in regards to inflammation.30 The male
obese group was twice as likely to have restrictive
pulmonary function, while the female obese group had no
significant association in the present study. The risk of
restrictive pulmonary function in the subjects who belong
to the obese and inflammatory group was more than three
times as high, suggesting that there is a joint effect of
a high percentage of body fat and an elevated CRP
concentration on restrictive pulmonary function. However,
the interactive effect of body fat and elevated CRP
concentration on impaired pulmonary function was
significant in women (P Z 0.004) but not in men
(P Z 0.497).
As mentioned earlier, obesity is associated with
restrictive lung function, and this association tends to be
stronger in men than in women.31e33 In our results, body
Table 3 Correlation between log CRP, body fat percentage, and various parameters.a
Variables Men (n Z 7083) Women (n Z 5704)
Log CRP Body fat percentage Log CRP Body fat percentage
r P-value r P-value r P-value r P-value
Age (yr) 0.066 <0.001 0.106 <0.001 0.212 <0.001 0.333 <0.001
Muscle mass (kg) 0.130 <0.001 0.145 <0.001 0.123 <0.001 0.157 <0.001
Fat mass (kg) 0.324 <0.001 0.912 <0.001 0.363 <0.001 0.632 <0.001
BMI (kg/m2) 0.285 <0.001 0.665 <0.001 0.404 <0.001 0.724 <0.001
Body fat percentage (%) 0.251 <0.001 1 0.340 <0.001 1
SBP (mmHg) 0.134 <0.001 0.235 <0.001 0.241 <0.001 0.309 <0.001
DBP (mmHg) 0.134 <0.001 0.248 <0.001 0.223 <0.001 0.285 <0.001
Fasting blood sugar (mmol/L) 0.094 <0.001 0.090 <0.001 0.200 <0.001 0.226 <0.001
Non-HDL-cholesterol (mmol/L)b 0.186 <0.001 0.249 <0.001 0.268 <0.001 0.313 <0.001
Log CRP 1 0.251 <0.001 1 0.340 <0.001
FVC(%) 0.092 <0.001 0.025 0.037 0.022 0.102 0.205 <0.001
FEV1(%) 0.043 <0.001 0.050 <0.001 0.045 0.001 0.026 0.049
FEV1/FVC 0.100 <0.001 0.087 <0.001 0.073 <0.001 0.125 <0.001
Regular exercisec 0.056 <0.001 0.004 0.733 0.009 0.481 0.008 0.479
Hypertensiond 0.102 <0.001 0.220 <0.001 0.204 <0.001 0.193 <0.001
Diabetese 0.050 <0.001 0.024 0.043 0.100 <0.001 0.020 0.096
Metabolic syndromef 0.224 <0.001 0.412 <0.001 0.282 <0.001 0.338 <0.001
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HDL, high-density
lipoprotein.
a Coefficients (r) and P-value were calculated using Pearson’s correlation analysis for continuous variables and Spearman rank
correlation for regular exercise, hypertension, diabetes, and metabolic syndrome.
b Non HDL-cholesterol was defined as the total cholesterol - HDL-cholesterol.
c Regular exercise was defined as  twice a week.
d Hypertension was defined as an SBP 140 mmHg, DBP  90 mmHg, or a history of the disorder.
e Diabetes was defined as fasting plasma glucose level 126 mg/dL or a history of the disorder.
f Metabolic syndrome was defined as having 3 or more of the following conditions: BMI 25 mg/m2; SBP 130 mmHg, DBP 85 mmHg,
or a history of the disorder; fasting plasma glucose 100 mg/dL or a history the disorder; triglyceride 150 mg/dL; HDL-cholesterol
<40 mg/dL for men, <50 mg/dL for women.
Body composition, C-reactive protein, and pulmonary function 1201fat percentage was significantly associated with restric-
tive lung function only in obese men, not in obese
women. Moreover, the risk of impaired lung function in
obese men was significant with a low CRP, which was notTable 4 Joint effects of CRP and body fat percentage on restri
Odds Ratio (95% CI)
Reference group Inflammatory
Men
Model 1a 1.00 1.23 (0.96e1
Model 2b 1.00 1.25 (0.93e1
Model 3c 1.00 1.19 (0.93e1
Women
Model 1a 1.00 1.28 (0.97e1
Model 2b 1.00 1.25 (0.95e1
Model 3c 1.00 1.26 (0.96e1
*P < 0.001.
a Model 1: adjusted for age and BMI.
b Model 2: adjusted for age, BMI, regular exercise, diabetes, hypert
c Model 3: adjusted for age, BMI, regular exercise, diabetes, hype
systolic blood pressure, and diastolic blood pressure.the case in women with low CRP. One of the reasons for
inconsistent results between men and women could be
explained by gender differences in the pattern of fat
distribution. Women generally have a higher percentagective pattern in men and women.
group Obese group Obese and
inflammatory group
.56) 2.06 (1.57e2.69)* 3.63 (2.70e4.87)*
.50) 2.00 (1.53e2.62)* 3.43 (2.54e4.62)*
.52) 2.01 (1.53e2.64)* 3.51 (2.60e4.74)*
.67) 1.07 (0.60e1.88) 3.66 (2.33e5.76)*
.64) 1.04 (0.60e1.84) 3.34 (2.11e5.28)*
.69) 1.02 (0.58e1.81) 3.32 (2.09e5.27)*
ension, and smoking.
rtension, smoking, fasting plasma glucose, non HDL-cholesterol,
1202 D.-H. Jung et al.of body fat than men,34 and body fat tends to be accu-
mulated in the gluteal-femoral region in women, whereas
men store more fat in the abdominal and visceral depot.35
Actually, the cut-off value of high fat percentage (>75
percentile) in women was higher than in men in our study.
The gender difference in the effect of obesity on
pulmonary function may arise from different fat distri-
bution between men and women, because visceral fat
rather than subcutaneous fat is strongly associated with
impaired lung function and low-grade systemic inflam-
mation.31,36 Thus, the association between fat accumula-
tion and restrictive pulmonary function in men could be
more significant than among women. The gender differ-
ence in body fat distribution could also explain differ-
ences in the interactive effect obesity and inflammation
on impaired pulmonary function.
We defined the cut-off points for inflammation and
obesity as 75 percentiles of CRP and body fat percentage.
There are publications reporting that 3.0 mg/L of CRP
level, the upper tertile of US adult population, may be
a high risk of cardiovascular disease in both men and
women.37,38 However, there may be gender and ethnic
differences in CRP distribution, because different ethnic-
ities and lifestyle factors may affect inflammatory
response in different manners.39,40 Some studies reported
that the CRP concentration of Asians may be lower than
Caucasian populations.41,42 Unfortunately, there is a lack
of information about the CRP distribution in Korean. Thus,
we defined the cut-off points for inflammation as 75
percentiles of CRP. Although body fat percentage may be
the measurement of obesity like BMI, there is insufficient
data defining obesity by body fat percentage, unlike BMI.
As shown in Table 3, body fat percentage was strongly
associated with BMI in both men and women, and the cut-
off value for obesity BMI 25 kg/m2 in East Asians corre-
spond to 62 percentile in men and 82 percentile in women
(not shown).
Our study has several limitations. Our study used a cross-
sectional design. Further understanding of the complex
interaction between body fat accumulation, low-grade
inflammation, and pulmonary function should be observed
in future studies. Second, the Center for Disease Control
and Prevention (CDC) and the American Heart Association
(AHA) guidelines recommended two separate CRP
measurements to consider within-individual variability.43
However, only one measurement of CRP was included in
the analysis and it was not possible to determine whether
an acute and brief episode of infection or chronic inflam-
mation was responsible for the correlation observed. To
minimize these random errors, we excluded subjects with
CRP levels >10 mg/L due to possible acute infection.
Finally, central obesity is indicated by waist circumference
rather than BMI, but we did not evaluate waist circumfer-
ence by manual measurements at the beginning of this
study.
In conclusion, the coexistence of body fat accumulation
and low-grade inflammation is associated with restrictive
pulmonary function in both men and women. Further
research is warranted to better understand the patho-
physiologic role of the joint effect of obesity and inflam-
mation in the development of impaired pulmonary
function.Conflict of interest statement
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